After the company has frequently clarified, it has closed the daily limit?
On the evening of March 15th,Peking University MedicineRe-post reminderannouncementSaid that the company has never carried out the research and development of new crown special drugs, and investors are requested to pay attention to investment risks and invest rationally. Previously, due to market rumors,Peking University MedicineIn cooperation with Japan’s Shionogi to develop special medicines for the new crown, the stock achieved five consecutive boards in one breath.
ććfive-link boardPeking University MedicineTo clarify again:
ććThe research and development of new crown specific drugs has never been carried out
On March 15th, Peking University Pharmaceuticals issued an announcement on abnormal fluctuations in stock trading. Peking University Pharmaceuticals stated that due to the accumulated deviation of the closing price increase of the company’s shares for two consecutive trading days, according to ShenzhensecuritiesThe relevant regulations of the exchange belong to the abnormal fluctuation of stock trading.
In response to the abnormal fluctuations in the company’s stock trading, Peking University Pharma has verified relevant matters. Recently, I noticed that there are rumors on the Internet that the company has cooperated with Japan’s Shionogi to develop special drugs for the new crown. Here, Peking University Medicine solemnly stated that the company has never conducted research and development of new crown special drugs, nor has it discussed cooperation with Japan’s Shionogi about new crown special drugs. Investors are advised not to believe online rumors, pay attention to investment risks, and invest rationally.
In addition, Peking University Pharmaceuticals also added that after verification, there is no information disclosed by the company in the early stage that needs to be corrected or supplemented; the company’s current operating conditions are normal, and the internal and external operating environment has not undergone major changes;shareholderThere are no other major matters about the company that should be disclosed but not disclosed by the actual controller, and there are no major matters involving the company that are in the planning stage.
As of the date of this announcement, the company’s 2021 annual report is still under preparation and does not existperformanceIn the case of information leakage, the company does not need to disclose the performance forecast, and the unpublished regular report data information is not provided to third parties other than the company’s audit institution.
ććThe strength of the sales department appearedDragon Tiger List
On March 15th, Peking University Medicine hit the daily limit again, closing at 12.00 yuan, with a deviation of 14.55%, a turnover rate of 18.29%, an amplitude of 4.58%, and a turnover of 1.3 billion yuan. The stock was also on the Dragon Tiger list for three consecutive trading days when its closing price rose 20% off value.
According to the data, a powerful sales department appeared on the Dragon and Tiger List of Peking University Pharmaceuticals.Buy three positions forChina Merchants SecuritiesIn the trading unit, the seat bought 20.5405 million yuan and sold 1.2503 million yuan, with a net purchase of 19.2902 million yuan. In the past three months, this seat has been listed 309 times, ranking 11th in strength.
In addition, the second place to buy isCITIC Construction InvestmentsecuritiesQingchun Road, Hangzhou, is a first-line hot money business department. The purchase amount on that day was 24,005,900 yuan; the four positions sold were also displayed as first-line hot money. HuaxinsecuritiesShanghai Songbin Road Sales Department sold 17.1939 million yuan on the same day.
ććPeking University’s share price nearly doubles
In fact, on March 13, Peking University Pharmaceuticals had issued an announcement on abnormal fluctuations in stock trading to remind investors of risks. Peking University Pharmaceuticals emphasized that the company has been concerned about recent media reports on the progress of the oral drug developed by Shionogi Pharmaceutical Company of Japan to treat the new coronavirus, and the company currently has no plans to cooperate with foreign manufacturers on drugs. The company is currently in the transition period of Founder Group’s restructuring. For the company’s main business and core products, please refer to the annual report disclosed by the company.
However, this prompt announcement did not dampen the enthusiasm of the funds. Subsequently, under the influence of the favorable sentiment of the new crown special medicine in the market, Peking University Pharmaceuticals closed 5 consecutive daily limits. Since January 28, the stock has nearly doubled. As of now, the stock has risen by more than 97%, and the current total market value is 7.152 billion yuan.
Regarding the above-mentioned clarification announcement, some investors believe that “tomorrow will open at the limit down.” “Tomorrow is dangerous.”
ććNew crown testing-related stocks are active
On March 11, the State Council issued a notice from the Comprehensive Team of the Joint Prevention and Control Mechanism for Novel Coronavirus Pneumonia. In order to further optimize the new coronavirus detection strategy and serve the needs of epidemic prevention and control, it was decided to add antigen testing as a supplement to nucleic acid testing.
As of March 13, 10 domestic companies have obtained the NMPA registration certificate for the new crown antigen detection kit, and the application scenarios of self-inspection have been released. On March 13, multiple terminals including offline pharmacies and e-commerce platforms can purchase self-testing products for COVID-19 antigens at home, opening up the channels for residents to purchase themselves.
The above news is superimposed on the repeated domestic epidemic situation, which makes the concept of new crown detection become the strongest hot spot in the two cities. Stimulated by the good news,Minovar5 boards for 6 days,Hot View CreaturesćHanyu PharmaceuticalćOrientćGuangshengtangWait for the stock price to rise.
ććGuolian SecuritiesIt is believed that the policy has activated the antigen market of 100 billion yuan, and the progress of the epidemic has expanded the use of antigens. Antigen has the function of positive primary screening and can be used as an effective supplement for nucleic acid detection. At present, 10 domestic companies have obtained the NMPA registration certificate, which cannot fully meet the needs of the country after the liberalization. More than 30 Chinese companies have obtained access in Europe and North America, and have carried out a large number of promotion and sales. The sensitivity and specificity have been verified to a considerable extent, and the feedback is good. It is expected to become a potential approved manufacturer.
ććSouthwest SecuritiesIt is pointed out that the current epidemic situation in my country is showing a severe situation of spreading in many places. The new crown antigen self-test products can be widely used in the general inspection after the outbreak, routine screening of key populations, and rapid entry testing. At the same time, community residents can also carry out Self-test, the future market space can be expected. In the short term, it is recommended to pay attention to the industry chain related to the self-testing of COVID-19 antigens at home, including antigen testing products, upstream raw materials, retail channels, etc.
On March 15, the State Food and Drug Administration held a party group (expanded) meeting. The meeting called for continuous efforts to ensure the quality and supply of new coronavirus vaccines, accelerate the approval and launch of new coronavirus treatment drugs and personal self-testing products for new coronavirus antigen detection reagents, strengthen the quality supervision of epidemic prevention products, and do a solid job in internal prevention and control. work, and fully serve to ensure the overall situation of epidemic prevention and control.
In addition, it is worth mentioning that the recent concept of new crown special drugs is a big bullChinese medicine, to achieve 9 days and 7 boards.In the news, the company hasPfizerThe right to operate the new crown oral drug in mainland China.
Previously,Chinese medicinesaid that the company andPfizerThe company signed an agreement and will be responsible for the period of the agreement (2022)PfizerCommercial operation of the company’s new coronavirus treatment drug PAXLOVID in the Chinese mainland market. but,Chinese medicineIt is emphasized that this product is a prescription drug, and it has not yet entered the national medical insurance and domestic new coronary pneumonia diagnosis and treatment programs. The final use and sales are affected by factors such as epidemic prevention and control, and there is great uncertainty. It is relatively small and has no significant impact on the company’s recent operating performance.
(Article source: Chinafundnewspaper)